On April, 2 WallStreet anticipated Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)’s earnings report, as reported by Faxor. After $-0.75 earnings per share was revealed previous quarter, analysts now see negative EPS growth of 20.00 % for Diffusion Pharmaceuticals Inc.. DFFN hit $4.4 during the last trading session after $0.6 change.Diffusion Pharmaceuticals Inc. has volume of 162,823 shares. Since March 6, 2018 DFFN has declined 62.73% and is downtrending. DFFN underperformed the S&P 500 by 67.10%.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action.The firm is valued at $14.86 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer.Last it reported negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.

For more Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) news released recently go to: Seekingalpha.com, Benzinga.com, Seekingalpha.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Diffusion Pharma up 71% on new TSC patent – Seeking Alpha” released on December 17, 2018, “84 Biggest Movers From Yesterday – Benzinga” on February 28, 2019, “Tilray and Equillium among healthcare gainers; ContraFect and Diffusion Pharmaceuticals among losers – Seeking Alpha” with a publish date: December 18, 2018, “56 Biggest Movers From Yesterday – Benzinga” and the last “Diffusion Pharma executes 1:15 reverse split – Seeking Alpha” with publication date: December 14, 2018.